8 Best 3d Printing for December 2025
Welcome to the Value Sense Blog, your resource for insights on the stock market! At Value Sense, we focus on intrinsic value tools and offer stock ideas with undervalued companies. Dive into our research products and learn more about our unique approach at valuesense.io
Explore diverse stock ideas covering technology, healthcare, and commodities sectors. Our insights are crafted to help investors spot opportunities in undervalued growth stocks, enhancing potential returns. Visit us to see evaluations and in-depth market research.
Market Overview & Selection Criteria
The 3D printing and advanced manufacturing sector represents a compelling opportunity for value-focused investors seeking exposure to transformative industrial technologies. This collection of eight stocks spans software-driven design platforms, hardware manufacturers, and specialized medical device companies—all positioned within the broader digital manufacturing ecosystem.
Our selection methodology prioritizes companies with strong intrinsic value metrics, sustainable competitive advantages, and meaningful catalysts for growth. We've analyzed each company's quality rating, free cash flow generation, revenue growth trajectory, and return on invested capital to identify opportunities where market prices may not fully reflect underlying business fundamentals. This watchlist includes both established players with proven business models and emerging companies capturing market share in high-growth segments.
Featured Stock Analysis
Stock #1: Autodesk, Inc. (ADSK)
| Metric | Value |
|---|---|
| Market Cap | $64.5B |
| Quality Rating | 6.9 |
| Intrinsic Value | $236.2 |
| 1Y Return | 3.9% |
| Revenue | $6,882.0M |
| Free Cash Flow | $2,115.0M |
| Revenue Growth | 15.5% |
| FCF margin | 30.7% |
| Gross margin | 91.3% |
| ROIC | 21.3% |
| Total Debt to Equity | 101.2% |
Investment Thesis
Autodesk represents the software backbone of the digital design and manufacturing ecosystem, commanding a dominant position in computer-aided design (CAD), building information modeling (BIM), and product lifecycle management (PLM) solutions. With a market cap of $64.5 billion and annual revenue of $6.88 billion, Autodesk demonstrates the financial scale and profitability profile of a mature technology leader. The company's exceptional gross margin of 91.3% reflects the high-margin nature of software licensing, while its 30.7% free cash flow margin indicates strong cash generation capabilities that support shareholder returns and strategic investments.
The company's quality rating of 6.9 and return on invested capital of 21.3% underscore operational excellence and efficient capital deployment. With revenue growth of 15.5% and an intrinsic value estimate of $236.2, Autodesk offers exposure to the secular trend toward digital transformation in architecture, engineering, and construction industries. The 3.9% one-year return suggests the market may be underappreciating the company's recurring revenue model and expanding cloud-based offerings that serve the entire 3D printing and manufacturing workflow.
Key Catalysts
- Continued cloud migration driving higher-margin subscription revenue
- Expansion of generative AI capabilities within design software
- Growing adoption of digital twins and simulation technologies
- International market penetration in emerging economies
- Strategic acquisitions enhancing platform capabilities
Risk Factors
- Elevated debt-to-equity ratio of 101.2% requires monitoring
- Competition from open-source and lower-cost design alternatives
- Customer concentration risk within architecture and construction sectors
- Potential economic slowdown impacting enterprise software spending
- Integration challenges from past acquisitions
Stock #2: Xometry, Inc. (XMTR)
| Metric | Value |
|---|---|
| Market Cap | $2,985.5M |
| Quality Rating | 5.6 |
| Intrinsic Value | $40.3 |
| 1Y Return | 88.3% |
| Revenue | $642.8M |
| Free Cash Flow | ($13.7M) |
| Revenue Growth | 22.4% |
| FCF margin | (2.1%) |
| Gross margin | 39.3% |
| ROIC | (11.2%) |
| Total Debt to Equity | 122.1% |
Investment Thesis
Xometry operates a digital marketplace connecting engineers and manufacturers with on-demand manufacturing services, addressing a fragmented $500+ billion global manufacturing market. The company's market cap of $2.99 billion and revenue of $642.8 million position it as a high-growth player in the digital manufacturing space. The remarkable 88.3% one-year return reflects investor recognition of the company's disruptive business model, though the quality rating of 5.6 warrants careful consideration of operational metrics.
The company's 22.4% revenue growth rate demonstrates strong market adoption of its platform, capturing the secular shift toward just-in-time manufacturing and supply chain digitalization. Xometry's intrinsic value estimate of $40.3 suggests potential upside from current valuations, particularly as the platform scales and achieves profitability. The company's gross margin of 39.3% reflects the competitive nature of manufacturing services, while management's focus on operational leverage presents a pathway to improved cash flow generation as the platform matures.
Key Catalysts
- Expansion of manufacturing service offerings and geographic reach
- Achievement of positive free cash flow through operational leverage
- Increased adoption by enterprise customers seeking supply chain resilience
- Integration of AI-powered quoting and design optimization tools
- Potential strategic partnerships or acquisition by larger industrial players
Risk Factors
- Negative free cash flow of $13.7M and negative FCF margin of 2.1%
- Negative return on invested capital of 11.2% indicates current unprofitability
- High debt-to-equity ratio of 122.1% limits financial flexibility
- Dependence on manufacturing sector cyclicality
- Competitive pressure from established manufacturing networks and ERP providers
- Path to sustained profitability remains unproven
Stock #3: Proto Labs, Inc. (PRLB)
| Metric | Value |
|---|---|
| Market Cap | $1,211.4M |
| Quality Rating | 6.2 |
| Intrinsic Value | $39.5 |
| 1Y Return | 23.4% |
| Revenue | $518.4M |
| Free Cash Flow | $75.8M |
| Revenue Growth | 2.8% |
| FCF margin | 14.6% |
| Gross margin | 44.1% |
| ROIC | 1.5% |
| Total Debt to Equity | 0.4% |
Investment Thesis
Proto Labs operates a vertically integrated digital manufacturing platform specializing in rapid prototyping and short-run production for industrial customers. With a market cap of $1.21 billion and revenue of $518.4 million, the company has established itself as a trusted partner for engineers and product developers seeking fast turnaround times and quality manufacturing. The quality rating of 6.2 reflects solid operational fundamentals, while the conservative debt-to-equity ratio of 0.4 demonstrates prudent financial management and balance sheet strength.
The company's 14.6% free cash flow margin and positive free cash flow of $75.8 million indicate sustainable profitability and cash generation capabilities. While revenue growth of 2.8% appears modest, this reflects market maturity rather than business deterioration. The intrinsic value estimate of $39.5 and 23.4% one-year return suggest the market is recognizing Proto Labs' stable cash flows and potential for margin expansion through operational efficiency and technology investments. The company's 44.1% gross margin provides a solid foundation for profitability.
Key Catalysts
- Expansion of digital manufacturing capabilities and service offerings
- International market expansion and localization efforts
- Adoption of advanced manufacturing technologies and automation
- Growth in aerospace, automotive, and medical device sectors
- Potential strategic acquisitions to expand service portfolio
Risk Factors
- Modest revenue growth of 2.8% suggests market saturation in core segments
- Low return on invested capital of 1.5% indicates limited capital efficiency
- Dependence on industrial customer spending and capital budgets
- Competition from traditional job shops and emerging digital manufacturers
- Exposure to economic cyclicality in manufacturing sectors
Stock #4: Stratasys Ltd. (SSYS)
| Metric | Value |
|---|---|
| Market Cap | $747.6M |
| Quality Rating | 4.6 |
| Intrinsic Value | $12.6 |
| 1Y Return | -8.6% |
| Revenue | $561.5M |
| Free Cash Flow | ($5,261.0K) |
| Revenue Growth | (2.9%) |
| FCF margin | (0.9%) |
| Gross margin | 43.9% |
| ROIC | (9.0%) |
| Total Debt to Equity | 3.6% |
Investment Thesis
Stratasys represents one of the pioneering companies in 3D printing technology, with a market cap of $747.6 million and annual revenue of $561.5 million. The company's quality rating of 4.6 reflects current operational challenges that present both risks and potential recovery opportunities for value investors. The intrinsic value estimate of $12.6 suggests the market may be pricing in pessimistic assumptions about the company's turnaround prospects, creating a potential asymmetric opportunity for patient investors.
The company's 43.9% gross margin demonstrates the inherent profitability potential of 3D printing hardware and materials, though current execution challenges have prevented this margin advantage from flowing through to the bottom line. The negative one-year return of 8.6% and negative free cash flow of $5.26M indicate the company is navigating a challenging transition period. However, the company's strategic position in industrial 3D printing, combined with potential operational improvements and market recovery, could unlock significant value for investors with appropriate risk tolerance.
Key Catalysts
- Successful execution of operational restructuring and cost reduction initiatives
- Recovery in industrial 3D printing demand as manufacturing investment accelerates
- New product launches and technology innovations in advanced materials
- Expansion into high-growth vertical markets including aerospace and healthcare
- Potential strategic partnerships or consolidation within the 3D printing industry
Risk Factors
- Negative revenue growth of 2.9% indicates declining market demand
- Negative free cash flow and negative return on invested capital of 9.0%
- Quality rating of 4.6 reflects significant operational concerns
- Intense competition from larger technology companies entering 3D printing
- Dependence on capital equipment sales with long sales cycles
- Potential further deterioration if turnaround efforts fail to gain traction
Stock #5: Materialise NV (MTLS)
| Metric | Value |
|---|---|
| Market Cap | $357.4M |
| Quality Rating | 5.1 |
| Intrinsic Value | $18.0 |
| 1Y Return | -21.0% |
| Revenue | $274.7M |
| Free Cash Flow | $1,998.0K |
| Revenue Growth | 3.5% |
| FCF margin | 0.7% |
| Gross margin | 56.5% |
| ROIC | 2.1% |
| Total Debt to Equity | 0.0% |
Investment Thesis
Materialise operates a unique business model combining 3D printing software, services, and medical device manufacturing, with a market cap of $357.4 million and annual revenue of $274.7 million. The company's quality rating of 5.1 reflects mixed operational performance, though the zero debt-to-equity ratio provides significant financial flexibility for strategic investments and weathering market cycles. The intrinsic value estimate of $18.0 suggests potential upside from current valuations, particularly if the company successfully executes its medical device strategy.
The company's 56.5% gross margin—the highest among the 3D printing peers in this collection—reflects the value-added nature of its software and medical applications. While revenue growth of 3.5% appears modest, the company's diversified business model spanning software, services, and medical devices provides multiple growth vectors. The positive free cash flow of $2.0 million and minimal debt position Materialise as a financially stable platform for capturing opportunities in personalized medicine and surgical planning applications.
Key Catalysts
- Expansion of medical device applications and regulatory approvals
- Growth in personalized medicine and surgical planning solutions
- International expansion in emerging markets
- Software licensing and subscription revenue growth
- Potential strategic partnerships with healthcare providers and medical device companies
Risk Factors
- Negative one-year return of 21.0% indicates recent market skepticism
- Modest revenue growth of 3.5% suggests limited near-term acceleration
- Low return on invested capital of 2.1% indicates capital deployment challenges
- Regulatory risks associated with medical device business
- Dependence on 3D printing adoption in healthcare sector
- Competition from established medical device manufacturers
Stock #6: 3D Systems Corporation (DDD)
| Metric | Value |
|---|---|
| Market Cap | $258.7M |
| Quality Rating | 5.6 |
| Intrinsic Value | $11.8 |
| 1Y Return | -30.0% |
| Revenue | $391.7M |
| Free Cash Flow | ($94.2M) |
| Revenue Growth | (11.8%) |
| FCF margin | (24.1%) |
| Gross margin | 33.9% |
| ROIC | (34.0%) |
| Total Debt to Equity | 26.5% |
Investment Thesis
3D Systems represents a diversified 3D printing company with a market cap of $258.7 million and annual revenue of $391.7 million. The company's quality rating of 5.6 and negative one-year return of 30.0% reflect significant market challenges and operational difficulties that have pressured shareholder returns. The intrinsic value estimate of $11.8 suggests the market may be undervaluing the company's assets and intellectual property, though investors must carefully assess the company's ability to execute a turnaround strategy.
The company's 33.9% gross margin provides a foundation for profitability, but negative free cash flow of $94.2M and negative return on invested capital of 34.0% indicate severe operational challenges. The negative revenue growth of 11.8% suggests the company is losing market share or experiencing declining demand for its products and services. The debt-to-equity ratio of 26.5% reflects accumulated losses and financial stress, requiring careful monitoring of the company's financial stability and potential dilution risks.
Key Catalysts
- Successful execution of strategic restructuring and portfolio optimization
- New product launches targeting high-growth market segments
- Expansion of software and services revenue streams
- Recovery in industrial and healthcare 3D printing demand
- Potential strategic partnerships or acquisition by larger technology companies
Risk Factors
- Severe operational challenges with negative revenue growth of 11.8%
- Significant negative free cash flow and negative return on invested capital
- Quality rating of 5.6 reflects substantial business concerns
- Potential further deterioration and financial distress
- Intense competition from better-capitalized competitors
- Risk of dilution from potential capital raises or debt restructuring
- Execution risk on turnaround strategy
Most investors waste time on the wrong metrics. We've spent 10,000+ hours perfecting our value investing engine to find what actually matters.
Want to see what we'll uncover next - before everyone else does?
Find Hidden Gems First!
Stock #7: Monogram Orthopaedics, Inc. (MGRM)
| Metric | Value |
|---|---|
| Market Cap | $213.1M |
| Quality Rating | 5.9 |
| Intrinsic Value | $1.3 |
| 1Y Return | 158.6% |
| Revenue | $0.0 |
| Free Cash Flow | ($7,562.7K) |
| Revenue Growth | (100.0%) |
| FCF margin | N/A |
| Gross margin | N/A |
| ROIC | 2,212.7% |
| Total Debt to Equity | 3.4% |
Investment Thesis
Monogram Orthopaedics represents an early-stage medical device company specializing in personalized orthopedic solutions, with a market cap of $213.1 million. The company's remarkable 158.6% one-year return reflects investor enthusiasm for its innovative approach to orthopedic surgery, though the quality rating of 5.9 and limited revenue generation warrant careful due diligence. The intrinsic value estimate of $1.3 appears disconnected from current market valuations, suggesting either significant upside potential or valuation concerns that require investigation.
The company's zero revenue and negative free cash flow of $7.56M indicate it remains in a pre-revenue or early commercialization phase, typical of emerging medical device companies. The extraordinary ROIC figure of 2,212.7% reflects the mathematical artifact of minimal revenue base rather than operational efficiency. Investors considering this stock should recognize it as a high-risk, high-reward opportunity dependent on successful product commercialization, regulatory approvals, and market adoption of its personalized orthopedic solutions.
Key Catalysts
- Regulatory approvals and market clearances for core products
- Successful commercialization and adoption by orthopedic surgeons
- Expansion of product portfolio and surgical applications
- Strategic partnerships with hospital systems and medical device distributors
- Potential acquisition by larger medical device companies
Risk Factors
- Pre-revenue or early-stage company with significant execution risk
- Negative free cash flow indicates ongoing cash burn
- Dependence on successful regulatory approvals and market adoption
- Competition from established orthopedic device manufacturers
- Limited operating history and unproven business model
- Potential dilution from future capital raises
- High risk of total loss if commercialization efforts fail
Stock #8: Boxlight Corporation (BOXL)
| Metric | Value |
|---|---|
| Market Cap | $3,165.9K |
| Quality Rating | 5.5 |
| Intrinsic Value | $149.9 |
| 1Y Return | -57.7% |
| Revenue | $106.6M |
| Free Cash Flow | ($384.0K) |
| Revenue Growth | (29.3%) |
| FCF margin | (0.4%) |
| Gross margin | 32.6% |
| ROIC | (43.8%) |
| Total Debt to Equity | 493.4% |
Investment Thesis
Boxlight operates in the educational technology and display solutions market, with a market cap of $3.17 million and annual revenue of $106.6 million. The company's quality rating of 5.5 reflects operational challenges, while the negative one-year return of 57.7% indicates significant shareholder value destruction. The intrinsic value estimate of $149.9 appears substantially disconnected from current market valuations, suggesting either severe valuation concerns or potential recovery opportunities for contrarian investors.
The company's 32.6% gross margin provides a foundation for profitability, but negative free cash flow of $384K and negative return on invested capital of 43.8% indicate operational difficulties. The severe negative revenue growth of 29.3% suggests the company is experiencing significant market headwinds or losing competitive position. Most concerning is the debt-to-equity ratio of 493.4%, indicating extreme financial leverage and potential solvency concerns that require immediate attention from prospective investors.
Key Catalysts
- Stabilization of revenue and return to growth trajectory
- Successful execution of cost reduction and operational efficiency initiatives
- Recovery in educational technology spending post-pandemic
- New product launches and market expansion
- Potential strategic partnerships or acquisition
Risk Factors
- Severe revenue decline of 29.3% indicates significant market challenges
- Negative free cash flow and negative return on invested capital
- Extreme debt-to-equity ratio of 493.4% creates solvency concerns
- Quality rating of 5.5 reflects substantial operational concerns
- Potential financial distress or bankruptcy risk
- Intense competition in educational technology market
- Dependence on education sector spending and budget cycles
- High risk of total loss for equity investors
Portfolio Diversification Insights
This eight-stock collection spans multiple segments within the advanced manufacturing and 3D printing ecosystem, providing meaningful diversification across business models, market maturity stages, and risk profiles.
Sector and Business Model Breakdown:
The portfolio includes software and platform companies (Autodesk, Xometry), hardware manufacturers (Stratasys, 3D Systems, Proto Labs), specialized medical device companies (Materialise, Monogram Orthopaedics), and educational technology (Boxlight). This diversification reduces dependence on any single market segment or technology platform.
Financial Profile Distribution:
The collection ranges from highly profitable, cash-generative businesses like Autodesk with 30.7% free cash flow margins to early-stage companies like Monogram Orthopaedics burning cash during commercialization phases. This spectrum allows investors to construct portfolios matching their risk tolerance and investment horizon. Conservative investors might focus on Autodesk and Proto Labs, while growth-oriented investors might emphasize Xometry and Monogram Orthopaedics.
Quality Rating Spectrum:
Quality ratings range from 4.6 (Stratasys) to 6.9 (Autodesk), reflecting varying levels of operational excellence and financial health. This distribution enables portfolio construction balancing stability with growth potential, allowing investors to calibrate exposure to turnaround situations versus established market leaders.
Growth and Valuation Characteristics:
Revenue growth rates span from negative (Stratasys at -2.9%, 3D Systems at -11.8%, Boxlight at -29.3%) to positive (Xometry at 22.4%, Autodesk at 15.5%). This diversity provides exposure to both mature, cash-generative businesses and high-growth companies capturing emerging market opportunities. The intrinsic value estimates suggest potential upside across the portfolio, though with varying confidence levels based on quality ratings and financial metrics.
Market Timing & Entry Strategies
Phased Entry Approach:
Rather than deploying capital simultaneously across all eight positions, consider a phased entry strategy that allows for dollar-cost averaging and reduces timing risk. Begin with established, profitable companies like Autodesk and Proto Labs to establish a stable portfolio foundation, then gradually add exposure to higher-growth, higher-risk opportunities like Xometry and Monogram Orthopaedics as conviction develops.
Valuation-Based Entry Points:
Monitor each company's intrinsic value estimates relative to current market prices. Autodesk's intrinsic value of $236.2 provides a clear valuation benchmark, as does Proto Labs' $39.5 estimate. When market prices approach or fall below intrinsic value estimates, these represent compelling entry opportunities. Conversely, when prices significantly exceed intrinsic values, consider waiting for better entry points or reducing position sizes.
Sector Cycle Considerations:
The 3D printing and advanced manufacturing sector exhibits cyclicality tied to industrial capital spending, technology adoption cycles, and economic conditions. Consider increasing exposure during periods of economic expansion and industrial investment, while reducing exposure during recessionary periods or when technology adoption appears to be slowing.
Risk-Based Position Sizing:
Allocate larger position sizes to higher-quality companies with proven business models and positive cash flows (Autodesk, Proto Labs), while maintaining smaller positions in turnaround situations or early-stage companies (Stratasys, 3D Systems, Monogram Orthopaedics). This approach balances portfolio risk while maintaining meaningful exposure to potential recovery situations.
Catalyst-Driven Timing:
Monitor company-specific catalysts including product launches, regulatory approvals, earnings announcements, and strategic partnerships. Consider increasing exposure ahead of anticipated positive catalysts, while reducing exposure if catalysts fail to materialize or prove disappointing.
Explore More Investment Opportunities
For investors seeking undervalued companies with high fundamental quality, our analytics team provides curated stock lists:
📌 50 Undervalued Stocks (Best overall value plays for 2025)
📌 50 Undervalued Dividend Stocks (For income-focused investors)
📌 50 Undervalued Growth Stocks (High-growth potential with strong fundamentals)
🔍 Check out these stocks on the Value Sense platform for free!
More Articles You Might Like
- How VKTX (Viking Therapeutics) Makes Money in 2025: A Deep-Dive With Income Statement
- How NET (Cloudflare) Makes Money in 2025: A Deep-Dive With Income Statement
- How MASS (908 Devices) Makes Money in 2025: A Deep-Dive With Income Statement
- How CRVO (CervoMed) Makes Money in 2025: A Deep-Dive With Income Statement
- How GILD (Gilead Sciences) Makes Money in 2025: A Deep-Dive With Income Statement
FAQ Section
Q1: How were these stocks selected for this watchlist?
These eight stocks were selected based on ValueSense's fundamental analysis methodology, focusing on companies operating within the 3D printing and advanced manufacturing ecosystem. The selection process evaluated each company's intrinsic value relative to market price, quality ratings reflecting operational excellence, free cash flow generation, return on invested capital, and growth prospects. The collection intentionally spans multiple business models and risk profiles—from established software leaders to early-stage medical device companies—to provide diversified exposure to the sector while allowing investors to calibrate risk according to their preferences.
Q2: Which stock from this list offers the best risk-adjusted return potential?
Autodesk (ADSK) presents the most compelling risk-adjusted opportunity for conservative investors, combining a quality rating of 6.9, strong free cash flow generation (30.7% FCF margin), and proven business model with 15.5% revenue growth. Proto Labs (PRLB) offers an attractive alternative for investors seeking lower leverage (0.4 debt-to-equity ratio) and positive cash flows with a quality rating of 6.2. For growth-oriented investors with higher risk tolerance, Xometry (XMTR) presents significant upside potential despite current profitability challenges, supported by 22.4% revenue growth and an 88.3% one-year return. The "best" choice depends on individual risk tolerance, investment horizon, and portfolio objectives.
Q3: Should I invest in all eight stocks or focus on a subset for better diversification?
Portfolio construction should reflect your investment objectives, risk tolerance, and capital availability. Conservative investors might focus on the three highest-quality companies—Autodesk, Proto Labs, and Materialise—which collectively offer exposure to software, manufacturing services, and medical applications with quality ratings of 6.9, 6.2, and 5.1 respectively. Growth-oriented investors might emphasize Xometry and Monogram Orthopaedics for higher growth potential, while accepting greater volatility and execution risk. A balanced approach might allocate 40-50% to established players (Autodesk, Proto Labs), 30-40% to growth companies (Xometry, Materialise), and 10-20% to turnaround situations or early-stage opportunities (Stratasys, 3D Systems, Monogram Orthopaedics, Boxlight). This allocation provides meaningful diversification while maintaining focus on the sector thesis.
Q4: What are the biggest risks with these stock picks?
The primary risks vary by company but include: operational execution challenges (Stratasys, 3D Systems, Boxlight), negative free cash flow and profitability concerns (Xometry, 3D Systems, Boxlight), high financial leverage (Xometry, Stratasys, Boxlight), and dependence on sector adoption and capital spending cycles. Early-stage companies like Monogram Orthopaedics face regulatory and commercialization risks, while established players like Autodesk face competition from open-source alternatives and potential economic slowdown impacting enterprise software spending. Investors should carefully assess their risk tolerance and conduct thorough due diligence before investing, particularly in turnaround situations or early-stage companies where execution risk is elevated.
Q5: When is the best time to invest in these stocks?
Optimal timing depends on individual circumstances and market conditions. For established, profitable companies like Autodesk and Proto Labs, dollar-cost averaging over time reduces timing risk and captures opportunities across market cycles. For growth companies like Xometry, consider building positions during market weakness when valuations become more attractive. For turnaround situations like Stratasys and 3D Systems, timing should align with evidence of successful operational improvements and return to profitability. Monitor each company's quarterly earnings, product announcements, and strategic developments to identify catalysts that might influence valuations. Consider increasing exposure during periods of industrial expansion and technology adoption acceleration, while reducing exposure during economic uncertainty or when sector growth appears to be slowing.